# VivoSim Labs, INC.: financial statements, quarterly

VIVS · Nasdaq · CIK 1497253 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/vivs.md) · [Financials](/companies/vivs/financials.md) · [Filings](/companies/vivs/filings.md) · [Insiders](/companies/vivs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vivs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0000950170-24-124044.md) | [5.0](/filings/0000950170-25-022778.md) | [29.0 d](/filings/0000950170-25-082312.md) | [39.0](/filings/0000950170-25-107284.md) | [30.0](/filings/0001193125-25-269483.md) | [24.0](/filings/0001193125-26-046520.md) | [51.0 d](/filings/0001193125-26-303316.md) | [37.0](/filings/0001193125-26-346820.md) | [28.0](/filings/0001193125-25-269483.md) | [26.0](/filings/0001193125-26-046520.md) | [40.0 d](/filings/0001193125-26-303316.md) | [18.0](/filings/0001193125-26-346820.md) |
| Cost of revenue | $k | [0.0](/filings/0000950170-24-124044.md) | [0.0](/filings/0000950170-25-022778.md) | not reported | [2.0](/filings/0000950170-25-107284.md) | [1.0](/filings/0001193125-25-269483.md) | [2.0](/filings/0001193125-26-046520.md) | [0.0 d](/filings/0001193125-26-303316.md) | [0.0](/filings/0000950170-25-107284.md) | [0.0](/filings/0001193125-25-269483.md) | [0.0](/filings/0001193125-26-046520.md) | [0.0 d](/filings/0001193125-26-303316.md) | not reported |
| Research and development | $k | [1,335](/filings/0000950170-24-124044.md) | [1,434](/filings/0000950170-25-022778.md) | [1,063 d](/filings/0000950170-25-082312.md) | [1,402](/filings/0000950170-25-107284.md) | [984](/filings/0001193125-25-269483.md) | [1,780](/filings/0001193125-26-046520.md) | [859 d](/filings/0001193125-26-303316.md) | [1,001](/filings/0001193125-26-346820.md) | [923](/filings/0001193125-25-269483.md) | [1,140](/filings/0001193125-26-046520.md) | [1,125 d](/filings/0001193125-26-303316.md) | [1,132](/filings/0001193125-26-346820.md) |
| Selling, general and administrative | $k | [2,780](/filings/0000950170-24-124044.md) | [2,251](/filings/0000950170-25-022778.md) | [2,062 d](/filings/0000950170-25-082312.md) | [2,021](/filings/0000950170-25-107284.md) | [1,653](/filings/0001193125-25-269483.md) | [1,710](/filings/0001193125-26-046520.md) | [2,346 d](/filings/0001193125-26-303316.md) | [1,951](/filings/0001193125-26-346820.md) | [1,740](/filings/0001193125-25-269483.md) | [1,636](/filings/0001193125-26-046520.md) | [2,102 d](/filings/0001193125-26-303316.md) | [1,645](/filings/0001193125-26-346820.md) |
| Operating income | $k | [(4,115)](/filings/0000950170-24-124044.md) | [(3,680)](/filings/0000950170-25-022778.md) | [(3,096) d](/filings/0000950170-25-082312.md) | [(3,386)](/filings/0000950170-25-107284.md) | [(2,608)](/filings/0001193125-25-269483.md) | [(3,468)](/filings/0001193125-26-046520.md) | [(3,154) d](/filings/0001193125-26-303316.md) | [(2,915)](/filings/0001193125-26-346820.md) | [(2,635)](/filings/0001193125-25-269483.md) | [(2,750)](/filings/0001193125-26-046520.md) | [(3,187) d](/filings/0001193125-26-303316.md) | [(2,759)](/filings/0001193125-26-346820.md) |
| Interest expense | $k | not reported | [0.0](/filings/0000950170-25-022778.md) | not reported | [0.0](/filings/0000950170-25-107284.md) | [0.0](/filings/0001193125-25-269483.md) | [5.0](/filings/0001193125-26-046520.md) | [5.0 d](/filings/0001193125-26-303316.md) | [4.0](/filings/0001193125-26-346820.md) | [0.0](/filings/0001193125-25-269483.md) | [4.0](/filings/0001193125-26-046520.md) | [4.0 d](/filings/0001193125-26-303316.md) | [4.0](/filings/0001193125-26-346820.md) |
| Income tax | $k | [0.0](/filings/0000950170-24-124044.md) | [0.0](/filings/0000950170-25-022778.md) | [0.0 d](/filings/0000950170-25-082312.md) | [2.0](/filings/0000950170-25-107284.md) | [0.0](/filings/0001193125-25-269483.md) | [0.0](/filings/0001193125-26-046520.md) | [0.0 d](/filings/0001193125-26-303316.md) | [0.0](/filings/0001193125-26-346820.md) | [2.0](/filings/0001193125-25-269483.md) | [0.0](/filings/0001193125-26-046520.md) | [0.0 d](/filings/0001193125-26-303316.md) | [3.0](/filings/0001193125-26-346820.md) |
| Net income | $k | [(3,994)](/filings/0000950170-24-124044.md) | [(3,604)](/filings/0000950170-25-022778.md) | [(3,045) d](/filings/0000950170-25-082312.md) | [(3,344)](/filings/0000950170-25-107284.md) | [(2,549)](/filings/0001193125-25-269483.md) | [(3,447)](/filings/0001193125-26-046520.md) | [6,852 d](/filings/0001193125-26-303316.md) | [(2,843)](/filings/0001193125-26-346820.md) | [(2,545)](/filings/0001193125-25-269483.md) | [(2,691)](/filings/0001193125-26-046520.md) | [(5,764) d](/filings/0001193125-26-303316.md) | [(1,338)](/filings/0001193125-26-346820.md) |
| Diluted EPS | $ per share | [(0.46)](/filings/0000950170-24-124044.md) | [(0.40)](/filings/0000950170-25-022778.md) | not reported | [(2.74)](/filings/0000950170-25-107284.md) | [(1.68)](/filings/0001193125-25-269483.md) | [(2.28)](/filings/0001193125-26-046520.md) | not reported | [(1.14)](/filings/0001193125-26-346820.md) | [(0.98)](/filings/0001193125-25-269483.md) | [(1.03)](/filings/0001193125-26-046520.md) | not reported | [(0.25)](/filings/0001193125-26-346820.md) |
| Basic EPS | $ per share | [(0.46)](/filings/0000950170-24-124044.md) | [(0.40)](/filings/0000950170-25-022778.md) | not reported | [(2.74)](/filings/0000950170-25-107284.md) | [(1.68)](/filings/0001193125-25-269483.md) | [(2.28)](/filings/0001193125-26-046520.md) | not reported | [(1.14)](/filings/0001193125-26-346820.md) | [(0.98)](/filings/0001193125-25-269483.md) | [(1.03)](/filings/0001193125-26-046520.md) | not reported | [(0.25)](/filings/0001193125-26-346820.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.6](/filings/0000950170-24-124044.md) | [5.3](/filings/0000950170-25-022778.md) | [2.9](/filings/0000950170-25-082312.md) | [6.2](/filings/0000950170-25-107284.md) | [3.2](/filings/0001193125-25-269483.md) | [1.2](/filings/0001193125-26-046520.md) | [11.3](/filings/0001193125-26-303316.md) | [9.1](/filings/0001193125-26-346820.md) | [6.7](/filings/0001193125-25-269483.md) | [4.3](/filings/0001193125-26-046520.md) | [5.0](/filings/0001193125-26-346820.md) | [1.7](/filings/0001193125-26-346820.md) |
| Current assets | $m | [8.3](/filings/0000950170-23-062228.md) | [6.2](/filings/0000950170-24-012754.md) | [3.9](/filings/0000950170-25-082312.md) | [7.3](/filings/0000950170-24-090726.md) | [4.8](/filings/0000950170-24-124044.md) | [2.1](/filings/0000950170-25-022778.md) | [12.1](/filings/0001193125-26-303316.md) | [9.7](/filings/0000950170-25-107284.md) | [7.6](/filings/0001193125-25-269483.md) | [6.0](/filings/0001193125-26-046520.md) | [6.6](/filings/0001193125-26-346820.md) | [3.2](/filings/0001193125-26-346820.md) |
| Total assets | $m | [11.2](/filings/0000950170-23-062228.md) | [8.9](/filings/0000950170-24-012754.md) | [6.3](/filings/0000950170-25-082312.md) | [9.5](/filings/0000950170-24-090726.md) | [6.8](/filings/0000950170-24-124044.md) | [3.8](/filings/0000950170-25-022778.md) | [14.7](/filings/0001193125-26-303316.md) | [12.0](/filings/0000950170-25-107284.md) | [9.7](/filings/0001193125-25-269483.md) | [7.0](/filings/0001193125-26-046520.md) | [7.4](/filings/0001193125-26-346820.md) | [3.8](/filings/0001193125-26-346820.md) |
| Current liabilities | $m | [1.6](/filings/0000950170-23-062228.md) | [1.7](/filings/0000950170-24-012754.md) | [1.9](/filings/0000950170-25-082312.md) | [2.0](/filings/0000950170-24-090726.md) | [2.4](/filings/0000950170-24-124044.md) | [2.9](/filings/0000950170-25-022778.md) | [3.7](/filings/0001193125-26-303316.md) | [2.1](/filings/0000950170-25-107284.md) | [2.4](/filings/0001193125-25-269483.md) | [2.5](/filings/0001193125-26-046520.md) | [2.8](/filings/0001193125-26-346820.md) | [1.9](/filings/0001193125-26-346820.md) |
| Total liabilities | $m | [2.7](/filings/0000950170-23-062228.md) | [2.7](/filings/0000950170-24-012754.md) | [2.7](/filings/0000950170-25-082312.md) | [2.8](/filings/0000950170-24-090726.md) | [3.1](/filings/0000950170-24-124044.md) | [3.5](/filings/0000950170-25-022778.md) | [4.2](/filings/0001193125-26-303316.md) | [2.4](/filings/0000950170-25-107284.md) | [2.6](/filings/0001193125-25-269483.md) | [2.5](/filings/0001193125-26-046520.md) | [8.5](/filings/0001193125-26-346820.md) | [6.2](/filings/0001193125-26-346820.md) |
| Shareholders' equity | $m | [8.5](/filings/0000950170-23-062228.md) | [6.2](/filings/0000950170-24-012754.md) | [3.6](/filings/0000950170-25-082312.md) | [6.7](/filings/0000950170-24-090726.md) | [3.7](/filings/0000950170-24-124044.md) | [0.4](/filings/0000950170-25-082312.md) | [10.5](/filings/0001193125-26-303316.md) | [9.5](/filings/0000950170-25-107284.md) | [7.1](/filings/0001193125-25-269483.md) | [4.4](/filings/0001193125-26-046520.md) | [(1.1)](/filings/0001193125-26-346820.md) | [(2.3)](/filings/0001193125-26-346820.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,149) d](/filings/0000950170-24-124044.md) | [(3,522) d](/filings/0000950170-25-022778.md) | [(2,671) d](/filings/0000950170-25-082312.md) | [(2,983)](/filings/0000950170-25-107284.md) | [(2,642) d](/filings/0001193125-25-269483.md) | [(1,801) d](/filings/0001193125-26-046520.md) | [(2,035) d](/filings/0001193125-26-303316.md) | [(3,940)](/filings/0001193125-26-346820.md) | [(2,378) d](/filings/0001193125-25-269483.md) | [(2,271) d](/filings/0001193125-26-046520.md) | [(2,238) d](/filings/0001193125-26-303316.md) | [(3,213)](/filings/0001193125-26-346820.md) |
| Capital expenditure | $k | [27.0 d](/filings/0000950170-24-124044.md) | [0.0 d](/filings/0000950170-25-022778.md) | [0.0 d](/filings/0000950170-25-082312.md) | [0.0](/filings/0000950170-24-090726.md) | [13.0 d](/filings/0001193125-25-269483.md) | [0.0 d](/filings/0001193125-26-046520.md) | [0.0 d](/filings/0001193125-26-303316.md) | [0.0](/filings/0001193125-26-346820.md) | [0.0 d](/filings/0001193125-25-269483.md) | [0.0 d](/filings/0001193125-26-046520.md) | [0.0 d](/filings/0001193125-26-303316.md) | [23.0](/filings/0001193125-26-346820.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [8,712](/filings/0000950170-23-062228.md) | [8,714](/filings/0000950170-24-012754.md) | [8,717](/filings/0000950170-24-090726.md) | [8,719](/filings/0000950170-24-124044.md) | [9,115](/filings/0000950170-25-022778.md) | [1,222](/filings/0000950170-25-107284.md) | [1,500](/filings/0001193125-25-269483.md) | [1,505](/filings/0001193125-26-046520.md) | [2,504](/filings/0001193125-26-346820.md) | [2,605](/filings/0001193125-25-269483.md) | [2,608](/filings/0001193125-26-046520.md) | [5,239](/filings/0001193125-26-346820.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,850,612 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-346820.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.